BridgeBio Pharma, Inc. Interest Expense Nonoperating
BridgeBio Pharma, Inc. (BBIO) reported Interest Expense Nonoperating of $13.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-10
- BridgeBio Pharma, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $13.28M, a 14.40% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $12.94M, a 28.58% decline year-over-year.
- BridgeBio Pharma, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $11.64M, a 45.93% decline year-over-year.
- BridgeBio Pharma, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $11.74M, a 49.10% decline year-over-year.
- BridgeBio Pharma, Inc. interest expense nonoperating for fiscal 2025 was $53.10M, a 41.64% decline from fiscal 2024.
- BridgeBio Pharma, Inc. interest expense nonoperating for fiscal 2024 was $90.99M, a 11.94% increase from fiscal 2023.
- BridgeBio Pharma, Inc. interest expense nonoperating for fiscal 2023 was $81.29M, a 1.06% increase from fiscal 2022.
- BridgeBio Pharma, Inc. interest expense nonoperating for fiscal 2022 was $80.44M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 3 month as first filed | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 6 month as first filed | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month | Interest Expense Nonoperating 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.28M 10-Q · filed 2026-08-10 | $26.22M 10-Q · filed 2026-08-10 | $37.86M derived: sum of 3 quarters · filed 2026-08-10 | $49.59M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $12.94M 10-Q · filed 2026-05-07 | $24.58M derived: sum of 2 quarters · filed 2026-05-07 | $36.32M derived: sum of 3 quarters · filed 2026-05-07 | $47.92M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $11.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $23.38M derived: sum of 2 quarters · filed 2026-02-24 | $34.98M derived: sum of 3 quarters · filed 2026-08-10 | $53.10M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $11.74M 10-Q · filed 2025-10-29 | $23.35M derived: sum of 2 quarters · filed 2026-08-10 | $41.47M 10-Q · filed 2025-10-29 | $62.99M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $11.61M 10-Q · filed 2026-08-10 | $37.64M 10-Q · filed 2025-08-05 | $29.73M 10-Q · filed 2026-08-10 | $79.78M 10-Q · filed 2025-08-05 | $51.25M derived: sum of 3 quarters · filed 2026-08-10 | $74.31M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $18.12M 10-Q · filed 2026-05-07 | $42.14M 10-Q · filed 2025-04-29 | $39.64M derived: sum of 2 quarters · filed 2026-05-07 | $62.70M derived: sum of 3 quarters · filed 2026-05-07 | $85.64M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $21.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $44.58M derived: sum of 2 quarters · filed 2026-02-24 | $67.52M derived: sum of 3 quarters · filed 2026-02-24 | $90.99M 10-K · filed 2026-02-24 | $99.29M 10-K · filed 2025-02-20 | ||
| 2024-09-30 | $23.06M 10-Q · filed 2025-10-29 | $46.00M derived: sum of 2 quarters · filed 2025-10-29 | $69.47M 10-Q · filed 2025-10-29 | $89.74M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | $22.94M 10-Q · filed 2025-08-05 | $46.41M 10-Q · filed 2025-08-05 | $66.68M derived: sum of 3 quarters · filed 2026-02-24 | $86.98M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-03-31 | $23.47M 10-Q · filed 2025-04-29 | $43.74M derived: sum of 2 quarters · filed 2026-02-24 | $64.05M derived: sum of 3 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $20.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $40.57M derived: sum of 2 quarters · filed 2026-02-24 | $81.29M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $20.31M 10-Q · filed 2024-11-12 | $61.02M 10-Q · filed 2024-11-12 | |||||
| 2022-12-31 | $80.44M 10-K · filed 2025-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |